Your session is about to expire
← Back to Search
Apolipoprotein A-I [human] (apoA-I) for Acute Coronary Syndrome (AEGIS-II Trial)
AEGIS-II Trial Summary
This trial will test if CSL112 can reduce the risk of major adverse cardiovascular events in people with acute coronary syndrome.
- Acute Coronary Syndrome
AEGIS-II Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAEGIS-II Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AEGIS-II Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You do not have any signs of sudden kidney damage.You are currently experiencing unstable blood pressure or heart rate.You have a known allergy or sensitivity to soybeans, peanuts, or albumin.
- Group 1: Placebo
- Group 2: CSL112
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are signed up to take part in this research project?
"Per the information available on clinicaltrials.gov, this trial is currently seeking patients for enrollment. The study was first posted on March 21st, 2018 and has since been updated on October 10th, 2022. A total of 18200 individuals are needed at 100 different sites."
At how many different hospitals or research facilities can people participate in this trial?
"This experiment is looking for participants at 8400572 - AtlantiCare Regional Medical Center, 8401178 - Jersey Shore University Medical Center Meridian Health, and 8400489 - Duke University Hospital as well as 100 other facilities."
Are patients currently being signed up for this clinical trial?
"Yes, the trial is still looking for participants. The initial posting was on March 21st, 2018 and the clinicaltrials.gov page was updated as recently as October 10th, 2022."
Does apoA-I have the potential to harm people?
"Apolipoprotein A-I [human] (apoA-I) has received a safety score of 3. This is based on the fact that it is a Phase 3 trial, meaning there is some data supporting efficacy and multiple rounds of data supporting safety."
Share this study with friends
Copy Link
Messenger